What is the current stock price of Galecto, Inc. (GLTO)?

As of the latest market data, Galecto, Inc. (GLTO) is trading at $25.95. The stock has seen a gain of 0.23% today.

Does Galecto, Inc. (GLTO) pay a dividend?

Based on current data, Galecto, Inc. does not have a confirmed active dividend policy.

What is the market cap of Galecto, Inc.?

The current market capitalization of Galecto, Inc. (GLTO) is approximately unavailable.

GLTO

Galecto, Inc.·Healthcare

25.95

0.232%(+0.06)

Market Open

Last Updated: — ET

52W L: $2.0152W H: $38.33

GLTO NEWS

zacks.com

Apr 20

What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?

Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.

defenseworld.net

Mar 4

Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Galecto, Inc. (NASDAQ: GLTO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and two

defenseworld.net

Mar 2

Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February

Galecto, Inc. (NASDAQ: GLTO - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 277,004 shares, a growth of 86.6% from the January 29th total of 148,474 shares. Approximately 19.4% of the company's stock are short sold. Based

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2020-10-29

Beta

1.57

Websitegalecto.com↗